

# Management of methotrexate-induced renal failure without glucarpidase

I. Bilbao, A. De Basagoiti, M.A. Gil, Z. Baskaran, A. Belaustegui, J. Hernandez, B. Baza, L. Serrano, A. Bustinza, B. San Jose  
Hospital Universitario Cruces, Pharmacy Department, Barakaldo (Bizkaia), Spain. [idoia.bilbaomeseguer@osakidetza.net](mailto:idoia.bilbaomeseguer@osakidetza.net)

Glucarpidase (Voraxaze®) is effective in the treatment of high dose methotrexate (MTX)-induced renal dysfunction. However, glucarpidase is not always necessary for the treatment of this condition. Its high cost and availability issues, as well as other risks, complicate the decision of using it or not.

## Objective

To describe the evolution of a pediatric patient with MTX-induced renal failure.


## Methods

A 13 year-old girl with acute lymphoblastic leukaemia (consolidation therapy) developed a MTX-induced acute renal failure which was managed without glucarpidase.

## Results

### CHEMOTHERAPY

- MTX 5g/m<sup>2</sup> + oral mercaptopurine 30mg/m<sup>2</sup> + triple intrathecal therapy.
- There were no pharmacological interactions between MTX and the rest of the girl's treatment.



## Conclusions

An early intervention with supportive treatment based on folinic acid, hyperhydration and urine alkalinization was effective in the management of MTX induced renal toxicity.